{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T20:21:52Z","timestamp":1785529312809,"version":"3.56.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82160464"],"award-info":[{"award-number":["82160464"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This study aims to evaluate the efficacy and safety of programmed cell death protein 1 (PD-1) blockade in combination with chemotherapy for patients with advanced hepatoid adenocarcinoma of the stomach (HAS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>This study retrospectively collected data from 25 patients with advanced HAS who received first-line PD-1 blockade combined with chemotherapy across 6 centers between January 2018 and January 2024. Progression-free survival and overall survival were assessed using Kaplan-Meier curves.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This study included 25 patients with HAS, all of whom received a first-line treatment regimen combining PD-1 blockade and chemotherapy. The objective response rate and disease control rate were 76.0% and 88.0%, respectively. The median follow-up time was 13.1\u2009months, with a median progression-free survival of 10.2\u2009months (95% CI, 6.3-14.1) and a median overall survival of 20.3\u2009months (95% CI, 11.3-29.4). A total of 20 patients (80.0%) experienced adverse reactions of varying degrees, with white blood cell count decreased (12, 48.0%) being the most common adverse event. Two patients experienced fatal adverse events (grade 5), both of which were unrelated to the PD-1 blockade.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Patients with HAS can derive survival benefits from first-line treatment with PD-1 blockade combined with chemotherapy, and the treatment is well tolerated. Furthermore, this pathological subtype may serve as a predictive indicator of favorable efficacy for PD-1 blockade, regardless of the patients\u2019 programmed death-ligand 1 combined positive score.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf312","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T11:48:06Z","timestamp":1758628086000},"source":"Crossref","is-referenced-by-count":2,"title":["A multicenter retrospective study of PD-1 blockade plus chemotherapy as first-line therapy in advanced hepatoid adenocarcinoma of the stomach"],"prefix":"10.1093","volume":"30","author":[{"given":"Jingru","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Oncology, the First Affiliated Hospital, Jiangxi Medical College, Nanchang University , Nanchang, Jiangxi 330000,","place":["P.R.China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinbo","family":"Zhan","sequence":"additional","affiliation":[{"name":"Department of Oncology, the First Affiliated Hospital, Jiangxi Medical College, Nanchang University , Nanchang, Jiangxi 330000,","place":["P.R.China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Rao","sequence":"additional","affiliation":[{"name":"Department of Gastric Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine , Guangzhou, Guangdong 510000,","place":["P.R.China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Cardiac Vascular Surgery, The First Affiliated Hospital of Soochow University, Suzhou Medical College, Soochow University , Suzhou, Jiangsu 215000,","place":["P.R.China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"He","sequence":"additional","affiliation":[{"name":"Department of Oncology, the First Affiliated Hospital, Jiangxi Medical College, Nanchang University , Nanchang, Jiangxi 330000,","place":["P.R.China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Oncology, the First Affiliated Hospital, Jiangxi Medical College, Nanchang University , Nanchang, Jiangxi 330000,","place":["P.R.China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4142-8903","authenticated-orcid":false,"given":"Jianhua","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Nanfang Hospital, Southern Medical University , Guangzhou, Guangdong 510515,","place":["P.R.China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Gastric Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine , Guangzhou, Guangdong 510000,","place":["P.R.China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8734-584X","authenticated-orcid":false,"given":"Xiaojun","family":"Xiang","sequence":"additional","affiliation":[{"name":"Department of Oncology, the First Affiliated Hospital, Jiangxi Medical College, Nanchang University , Nanchang, Jiangxi 330000,","place":["P.R.China"]},{"name":"Department of the Rare Disease Center, the First Affiliated Hospital, Jiangxi Medical College, Nanchang University , Nanchang, Jiangxi 330000,","place":["P.R.China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"2025103007270080900_oyaf312-B1","first-page":"209","article-title":"Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2025103007270080900_oyaf312-B2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.bpg.2012.12.007","article-title":"Precancerous lesions in the stomach: from biology to clinical patient management","volume":"27","author":"Rugge","year":"2013","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"2025103007270080900_oyaf312-B3","first-page":"264","article-title":"Current treatment and recent progress in gastric cancer","volume":"71","author":"Joshi","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2025103007270080900_oyaf312-B4","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of her2-positive advanced gastric or gastro-oesophageal junction cancer (toga): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet (London, England)"},{"key":"2025103007270080900_oyaf312-B5","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(23)02033-0","article-title":"Pembrolizumab plus trastuzumab and chemotherapy for her2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 keynote-811 randomised placebo-controlled trial","volume":"402","author":"Janjigian","year":"2023","journal-title":"Lancet (London, England)"},{"key":"2025103007270080900_oyaf312-B6","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1001\/jama.2023.19918","article-title":"Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the orient-16 randomized clinical trial","volume":"330","author":"Xu","year":"2023","journal-title":"JAMA"},{"key":"2025103007270080900_oyaf312-B7","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1200\/JCO.23.01601","article-title":"First-line nivolumab plus chemotherapy for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 3-year follow-up of the phase iii checkmate 649 trial","volume":"42","author":"Janjigian","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025103007270080900_oyaf312-B8","doi-asserted-by":"crossref","first-page":"167","DOI":"10.6004\/jnccn.2022.0008","article-title":"Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Ajani","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"2025103007270080900_oyaf312-B9","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/1097-0142(19850815)56:4<840::AID-CNCR2820560423>3.0.CO;2-E","article-title":"An AFP-producing gastric carcinoma with features of hepatic differentiation. A case report","volume":"56","author":"Ishikura","year":"1985","journal-title":"Cancer"},{"key":"2025103007270080900_oyaf312-B10","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1002\/1097-0142(19930915)72:6<1827::AID-CNCR2820720606>3.0.CO;2-8","article-title":"Hepatoid adenocarcinoma of the stomach. A clinicopathologic and immunohistochemical analysis","volume":"72","author":"Nagai","year":"1993","journal-title":"Cancer"},{"key":"2025103007270080900_oyaf312-B11","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/his.13975","article-title":"The 2019 who classification of tumours of the digestive system","volume":"76","author":"Nagtegaal","year":"2020","journal-title":"Histopathology"},{"key":"2025103007270080900_oyaf312-B12","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3748\/wjg.v19.i3.321","article-title":"Clinicopathological characteristics in the differential diagnosis of hepatoid adenocarcinoma: a literature review","volume":"19","author":"Su","year":"2013","journal-title":"World J Gastroenterol"},{"key":"2025103007270080900_oyaf312-B13","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s10120-019-00965-5","article-title":"Hepatoid adenocarcinoma of the stomach: a unique subgroup with distinct clinicopathological and molecular features","volume":"22","author":"Wang","year":"2019","journal-title":"Gastric Cancer"},{"key":"2025103007270080900_oyaf312-B14","first-page":"6762","article-title":"Hepatoid adenocarcinoma of the stomach is a special and easily misdiagnosed or missed diagnosed subtype of gastric cancer with poor prognosis but curative for patients of pn0\/1: the experience of a single center","volume":"8","author":"Xie","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"2025103007270080900_oyaf312-B15","doi-asserted-by":"crossref","first-page":"463","DOI":"10.4103\/2319-4170.165001","article-title":"Clinicopathological features of gastric hepatoid adenocarcinoma","volume":"38","author":"Sureka","year":"2015","journal-title":"Biomed J"},{"key":"2025103007270080900_oyaf312-B16","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/jso.23073","article-title":"An analysis of clinicopathological features and prognosis by comparing hepatoid adenocarcinoma of the stomach with AFP-producing gastric cancer","volume":"106","author":"Liu","year":"2012","journal-title":"J Surg Oncol"},{"key":"2025103007270080900_oyaf312-B17","doi-asserted-by":"crossref","first-page":"128","DOI":"10.5114\/pjp.2018.76696","article-title":"Clinicopathologic study of 10 cases of gastric adenocarcinoma with hepatoid or enteroblastic differentiation","volume":"69","author":"Kuroda","year":"2018","journal-title":"Pol J Pathol"},{"key":"2025103007270080900_oyaf312-B18","doi-asserted-by":"crossref","first-page":"5554","DOI":"10.7150\/ijbs.71449","article-title":"Integrative analysis reveals a clinicogenomic landscape associated with liver metastasis and poor prognosis in hepatoid adenocarcinoma of the stomach","volume":"18","author":"Jiang","year":"2022","journal-title":"Int J Biol Sci"},{"key":"2025103007270080900_oyaf312-B19","doi-asserted-by":"crossref","first-page":"3000605221091095","DOI":"10.1177\/03000605221091095","article-title":"Effect of immune checkpoint inhibitors in patients with gastric hepatoid adenocarcinoma: a case report and literature review","volume":"50","author":"Sun","year":"2022","journal-title":"J Int Med Res"},{"key":"2025103007270080900_oyaf312-B20","doi-asserted-by":"crossref","first-page":"1133335","DOI":"10.3389\/fsurg.2023.1133335","article-title":"Pathologic complete response of hepatoid adenocarcinoma of the stomach after chemo-immunotherapy: a rare case report and literature review","volume":"10","author":"Zhou","year":"2023","journal-title":"Front Surg"},{"key":"2025103007270080900_oyaf312-B21","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/jclinpath-2017-204928","article-title":"Her2 is frequently overexpressed in hepatoid adenocarcinoma and gastric carcinoma with enteroblastic differentiation: a comparison of 35 cases to 334 gastric carcinomas of other histological types","volume":"71","author":"Fujimoto","year":"2018","journal-title":"J Clin Pathol"},{"key":"2025103007270080900_oyaf312-B22","doi-asserted-by":"crossref","first-page":"6710428","DOI":"10.1155\/2019\/6710428","article-title":"Hepatoid adenocarcinoma of stomach: emphasis on the clinical relationship with alpha-fetoprotein-positive gastric cancer","volume":"2019","author":"Chen","year":"2019","journal-title":"Biomed Res Int"},{"key":"2025103007270080900_oyaf312-B23","doi-asserted-by":"crossref","first-page":"110591","DOI":"10.1016\/j.ijscr.2024.110591","article-title":"Conversion hepatectomy after chemotherapy including nivolumab for multiple liver metastases of hepatoid adenocarcinoma of the stomach: a case report and literature review","volume":"125","author":"Shiozaki","year":"2024","journal-title":"Int J Surg Case Rep"},{"key":"2025103007270080900_oyaf312-B24","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (checkmate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet (London, England)"},{"key":"2025103007270080900_oyaf312-B25","doi-asserted-by":"crossref","first-page":"e078876","DOI":"10.1136\/bmj-2023-078876","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: rationale-305 randomised, double blind, phase 3 trial","volume":"385","author":"Qiu","year":"2024","journal-title":"BMJ."},{"key":"2025103007270080900_oyaf312-B26","doi-asserted-by":"crossref","first-page":"S1319","DOI":"10.1016\/j.annonc.2023.10.080","article-title":"Gemstone-303: prespecified progression-free survival (PFS) and overall survival (OS) final analyses of a phase III study of sugemalimab plus chemotherapy vs placebo plus chemotherapy in treatment-naive advanced gastric or gastroesophageal junction (G\/GEJ) adenocarcinoma","volume":"34","author":"Zhang","year":"2023","journal-title":"Ann Oncol."},{"key":"2025103007270080900_oyaf312-B27","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for her2-negative advanced gastric cancer (keynote-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf312\/64398967\/oyaf312.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/10\/oyaf312\/64398967\/oyaf312.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/10\/oyaf312\/64398967\/oyaf312.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:27:09Z","timestamp":1761823629000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf312\/8264377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf312","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,9,25]]},"article-number":"oyaf312"}}